



Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum

August 18, 2022

SALT LAKE CITY, Aug. 18, 2022 /PRNewswire/ -- [Recursion](#) (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it recently received a Prime Rating for ESG performance from the industry-renowned [Institutional Shareholder Services](#) (ISS), which is the first time Recursion has been ranked by ISS. The ISS ESG Corporate Rating provides an assessment of a company's environmental, social, and governance activity. A Prime Rating is awarded to companies with ESG performance above a sector-specific threshold and is defined by ISS as "absolute best in class".

"We are proud to receive a Prime Rating by ISS for ESG," said Chris Gibson, Ph.D., Co-Founder & CEO of Recursion. "As a company looking to revolutionize the drug discovery industry, it is critical that we focus on building a sustainable culture that not only fosters interdisciplinary work across healthcare and technology, but also achieves the highest standards in mitigating our environmental impact and creating an inclusive, diverse, and equitable workplace in order to drive long-term success in the years to come."



Additionally, on September 29, 2022, Recursion plans to participate in the **Goldman Sachs Global Sustainability Forum** to share more about its ESG strategy and connect with the ESG investor community.

Recursion's Prime Rating from ISS follows the release of Recursion's first ESG report earlier this year, which outlines the Company's approach, practices and goals in several important areas. As part of the report, Recursion announced long-term commitments focused on net-zero greenhouse gas emissions, workforce diversity, and philanthropy.

The full 2022 Recursion ESG Report can be found [here](#).

More information on ISS ESG Corporate Ratings can be found [here](#).

About Recursion

[Recursion](#) is the clinical-stage biotechnology company industrializing drug discovery by decoding biology. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world's largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of [BioHive](#), the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on [Twitter](#) and [LinkedIn](#).

Media Contact

Media@Recursion.com

Investor Contact

Investor@Recursion.com

Forward-Looking Statements

This document contains information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as "plan," "will," "expect," "anticipate," "intend," "believe," "potential," "continue," and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to insufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; the impact of the COVID-19 pandemic and force majeure events; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Quarterly Report on Form 10-Q and our Annual Report on Form 10-K. All forward-looking statements are based on management's current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

SOURCE Recursion